[Alpha Biz= Reporter Kim Minyoung] HLB Therapeutics has announced that its NK (Natural Killer) cell therapy, RGN-259, currently undergoing global Phase 3 trials, has been valued between approximately $1 billion and $3 billion by a leading U.S. evaluation firm.
The company, which is conducting concurrent Phase 3 trials in the U.S. and Europe, anticipates that the European trial may conclude by the end of this year. To assess RGN-259's value, HLB Therapeutics engaged a prestigious U.S. evaluation firm, aiming to finalize licensing deals with global partners based on this valuation.
The evaluation results indicate that RGN-259 could be worth about $1.8 billion, with potential to reach up to $3 billion. This high valuation reflects the substantial market size and growth potential in the U.S., as well as the expected market dominance upon regulatory approval.
Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)
